Study for Characterisation of Predictive Parameters of Clonal Evolution in Subjects With GATA2 Germline Mutation
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This trial is a translational, open-label, multi-site, retrospective and prospective cohort study of 250 patients aiming to characterize predictive parameters of clonal evolution in a population of subjects carrying the germline GATA2 mutation. This study will be conducted on a population of subjects either with previous germline GATA2 mutation identified or newly identified for germline GATA2 mutation in the context of routine care. Prospective cohort: 150 subjects will be included in this interventional prospective cohort study: * Alive subjects previously identified with a germline GATA2 mutation through the already existing "Neutropenia database"; * Subject identified in the investigating centers in the context of a newly identified germline GATA2 mutation. For each included patient, biological samples (blood and bone marrow samples) will be collected at baseline visit and then during 5 years, according to the samples taken in the standard practice. No additional sampling will be performed for the study. Retrospective cohort: Subjects (100 cases in total) previously identified with germline GATA2 mutation through the already existing "Neutropenia database" and with the following features may enter the retrospective cohort: * Deceased patients, * Lost to follow-up patients. Clinical follow-up data will be obtained from this database and/or patient's medical report. For each retrospective case, archived blood and bone marrow samples (collected in a sanitary setting) will be sent to sponsor's centralized unit for analysis.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Osoby w każdym wieku, u których stwierdzono mutację genu GATA2.
- •Pacjenci objęci opieką medyczną w ośrodkach prowadzących badanie.
- •Wyrażenie pisemnej zgody na udział w badaniu. W przypadku dzieci, zgoda ich opiekuna prawnego oraz potwierdzenie chęci udziału dziecka.
- •Dla pacjentów we Francji: ubezpieczenie zdrowotne.
✗ Disqualifies
- •Posiadanie mutacji genu GATA2 nabytej (nie odziedziczonej).
- •Sytuacje, które utrudniają wyrażenie zgody lub przestrzeganie zasad badania, według oceny lekarza.
Simplified criteria — AI translation
Trial details
- Last updated (source)
- September 30, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (24)
CHU Angers
Angers, France
CHU Bordeaux
Bordeaux, France
CHU de Caen
Caen, France
CHU Estaing
Clermont-Ferrand, France
CHU Dijon
Dijon, France
CHU de Grenoble
Grenoble, France
CHRU - Lille
Lille, France
IHOP Lyon
Lyon, France
CHU La Timone
Marseille, France
CHU Arnaud de Villeneuve
Montpellier, France
CHU Nantes
Nantes, France
CHU de Nice
Nice, France
Hôpital Armand Trousseau
Paris, France
Hôpital Robert Debré
Paris, France
Hôpital Saint-Louis
Paris, France
CHU Rennes
Rennes, France
CHU Hôpitaux de Rouen - Charles Nicolle
Rouen, France
CHU Saint-Etienne
Saint-Priest-en-Jarez, France
Hôpital Necker
Sèvres, France
CHU Strasbourg
Strasbourg, France
CHU Purpan - Hôpital des Enfants
Toulouse, France
Institut Universitaire Du Cancer Toulouse - Oncopole (Iuct-O)
Toulouse, France
CHRU de Tours
Tours, France
CHRU Nancy Hôpital d'enfants
Vandœuvre-lès-Nancy, France
Trial contact
Marlène PASQUET
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 10/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.